Participated · Series B · May 2022

MOMA Therapeutics discovers precision medicines by targeting molecular machines that underlie human disease, focusing on vulnerabilities tied to stepwise protein conformational changes. The company combines advances in biochemistry, biophysics, structural biology, chemistry and functional genomics to build its drug discovery platform. It has generated multiple oncology programs and aims to develop high-impact precision oncology medicines for patients with unmet medical needs. Proceeds from the recent financing will be used to further develop product opportunities and advance a rich pipeline of precision oncology programs toward the clinic. Launched in 2020, MOMA has bolstered its team and is financed by a group of prominent life sciences investors. The company is based in Cambridge, Mass., and has continued to expand its board and investor syndicate as it progresses its programs.